ew regimen of therapy in the treatment of human Brucellosis

Phase 2

• Conditions: Brucellosis.; Brucellosis due to Brucella melitensis

• Registration Number: IRCT2014042617430N1
• Lead Sponsor: Babol University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

After providing adequate information eligible patients volenteer will be enrolled in the study.
the patient had not received treatment, and also clinical signs and para clinical signs including, blood cultures, Wright test, 2ME and combs wright.
Exclusion criteria: pregnant women; children younger than 8 years old; endocarditis, meningitis and spondylitis patients.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Quantity of regulatory T cells. Timepoint: Before treatment,6 weeks after begining of treatment,6months after end of treatment. Method of measurement: Flow cytometric.;Brucella bacteria. Timepoint: Before treatment,6 weeks after begining of treatment,6months after end of treatment. Method of measurement: Blood culture.;??Antibody of serum. Timepoint: Before treatment,6 weeks after begining of treatment,6months after end of treatment. Method of measurement: Wright test,2ME,Coombs.